338 related articles for article (PubMed ID: 25901709)
21. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
22. Cleavage of BLOC1S1 mRNA by IRE1 Is Sequence Specific, Temporally Separate from XBP1 Splicing, and Dispensable for Cell Viability under Acute Endoplasmic Reticulum Stress.
Bright MD; Itzhak DN; Wardell CP; Morgan GJ; Davies FE
Mol Cell Biol; 2015 Jun; 35(12):2186-202. PubMed ID: 25870107
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
24. Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cells.
Wang FM; Galson DL; Roodman GD; Ouyang H
Exp Hematol; 2011 Oct; 39(10):999-1006. PubMed ID: 21723843
[TBL] [Abstract][Full Text] [Related]
25. ER stress signaling by regulated splicing: IRE1/HAC1/XBP1.
Back SH; Schröder M; Lee K; Zhang K; Kaufman RJ
Methods; 2005 Apr; 35(4):395-416. PubMed ID: 15804613
[TBL] [Abstract][Full Text] [Related]
26. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
27. Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells.
Lin YT; Chao CC
Oncotarget; 2015 Nov; 6(36):38999-9017. PubMed ID: 26517516
[TBL] [Abstract][Full Text] [Related]
28. Adaptation of the secretory pathway in cancer through IRE1 signaling.
Lhomond S; Pallares N; Barroso K; Schmit K; Dejeans N; Fazli H; Taouji S; Patterson JB; Chevet E
Methods Mol Biol; 2015; 1292():177-94. PubMed ID: 25804756
[TBL] [Abstract][Full Text] [Related]
29. Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis.
Zhong J; Xiu P; Dong X; Wang F; Wei H; Wang X; Xu Z; Liu F; Li T; Wang Y; Li J
Oncol Rep; 2015 Oct; 34(4):2142-50. PubMed ID: 26252057
[TBL] [Abstract][Full Text] [Related]
30. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
Firtina Karagonlar Z; Koc D; Iscan E; Erdal E; Atabey N
Cancer Sci; 2016 Apr; 107(4):407-16. PubMed ID: 26790028
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
32. IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response.
Lee K; Tirasophon W; Shen X; Michalak M; Prywes R; Okada T; Yoshida H; Mori K; Kaufman RJ
Genes Dev; 2002 Feb; 16(4):452-66. PubMed ID: 11850408
[TBL] [Abstract][Full Text] [Related]
33. Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells.
Li R; Yanjiao G; Wubin H; Yue W; Jianhua H; Huachuan Z; Rongjian S; Zhidong L
Oncotarget; 2017 Mar; 8(12):19354-19364. PubMed ID: 28423613
[TBL] [Abstract][Full Text] [Related]
34. Testicular hyperthermia induces Unfolded Protein Response signaling activation in spermatocyte.
Kim JH; Park SJ; Kim TS; Park HJ; Park J; Kim BK; Kim GR; Kim JM; Huang SM; Chae JI; Park CK; Lee DS
Biochem Biophys Res Commun; 2013 May; 434(4):861-6. PubMed ID: 23611781
[TBL] [Abstract][Full Text] [Related]
35. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
Liu J; Liu Y; Meng L; Ji B; Yang D
Int J Med Sci; 2017; 14(6):523-529. PubMed ID: 28638267
[No Abstract] [Full Text] [Related]
36. Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death.
Yi P; Higa A; Taouji S; Bexiga MG; Marza E; Arma D; Castain C; Le Bail B; Simpson JC; Rosenbaum J; Balabaud C; Bioulac-Sage P; Blanc JF; Chevet E
Mol Cancer Ther; 2012 Dec; 11(12):2610-20. PubMed ID: 23041544
[TBL] [Abstract][Full Text] [Related]
37. The molecular mechanisms of XBP-1 gene silencing on IRE1α-TRAF2-ASK1-JNK pathways in oral squamous cell carcinoma under endoplasmic reticulum stress.
Chen H; Yang H; Pan L; Wang W; Liu X; Ren X; Liu Y; Liu W; Zhang Y; Jiang L; Li K; Zhang B; Wang LX
Biomed Pharmacother; 2016 Feb; 77():108-13. PubMed ID: 26796273
[TBL] [Abstract][Full Text] [Related]
38. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
39. The role of the IRE1 pathway in PBDE-47-induced toxicity in human neuroblastoma SH-SY5Y cells in vitro.
Jiang C; Zhang S; Liu H; Zeng Q; Xia T; Chen Y; Kuang G; Zhao G; Wu X; Zhang X; Wang A
Toxicol Lett; 2012 Jun; 211(3):325-33. PubMed ID: 22543052
[TBL] [Abstract][Full Text] [Related]
40. Neuronal activity-dependent local activation of dendritic unfolded protein response promotes expression of brain-derived neurotrophic factor in cell soma.
Saito A; Cai L; Matsuhisa K; Ohtake Y; Kaneko M; Kanemoto S; Asada R; Imaizumi K
J Neurochem; 2018 Jan; 144(1):35-49. PubMed ID: 28921568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
